#Denmark #Roche Diagnostics #Nordic Bioscience #PRO-C3 #Herlev

Nordic Bioscience Launches PRO-C3 Test in Partnership with Roche Diagnostics

In an exciting announcement for the medical diagnostics community, Nordic Bioscience revealed that its innovative PRO-C3 test is now available on Roche Diagnostics' cobas analyzers. This rollout marks a significant step forward in liver health assessments, utilizing the Roche Elecsys® platform in combination with the ADAPT formula which includes age, diabetes status, PRO-C3 levels, and platelet count. The test aims to better evaluate the severity of liver fibrosis, a condition that contributes to approximately one in every 25 deaths worldwide.

Background on PRO-C3 and Its Significance

The PRO-C3 biomarker, developed by Nordic Bioscience, has undergone rigorous validation in their CAP-CLIA-certified laboratory in Denmark. This validation emphasizes Nordic Bioscience’s commitment to precision medicine and their aim to deliver tools that comply with the highest standards for regulatory approval. Over the past decade, Nordic Bioscience researchers have published over 250 studies focusing on the PRO-C3 biomarker, solidifying its role as a leader in the study of fibrotic diseases.

The introduction of PRO-C3 marks the first biomarker from Nordic Bioscience’s fibrotic panel to receive CE marking, paving the way for clinical integration. With 40% of deaths in the Western world linked to organ fibrosis such as liver disease, the availability of accurate and reliable diagnostic tools is increasingly critical.

Collaboration with Roche Diagnostics

The Elecsys PRO-C3 test represents a groundbreaking collaboration between Nordic Bioscience and Roche Diagnostics, aimed at making state-of-the-art diagnostic technology accessible worldwide. As stated by Morten Karsdal, CEO of Nordic Bioscience, “We are proud that our technology is now available globally to make a significant impact for patients.” This agreement underscores the commitment from both companies to improve health outcomes through innovative diagnostic solutions.

Impact on Patients and Healthcare Providers

For healthcare providers, the introduction of the PRO-C3 test signifies an enhancement in the arsenal available for liver disease assessment. It allows for a more nuanced understanding of liver health and fibrosis severity, enabling better patient management and personalized treatment approaches. For patients, timely and accurate diagnosis can lead to improved treatment options and better health outcomes.

The PRO-C3 test was previously available exclusively through Nordic Bioscience's laboratory services in Denmark, but with the collaboration with Roche, it now has broader reach and application. This advancement aligns with the current trends in healthcare towards precision medicine, where treatments and diagnostics are tailored to individual patient needs.

Future Directions for Nordic Bioscience

Looking ahead, Nordic Bioscience strives to continue its innovation in biomarker development using its proprietary Neoepitope technology. This unique expertise allows them to create biomarkers that enable rapid and objective decision-making in clinical trials, while also offering tangible benefits in a diagnostic setting for patients.

For more information about the PRO-C3 test and its clinical applications, interested parties can visit Nordic Bioscience's official website.

Nordic Bioscience’s ongoing commitment to advancing biomarker technology highlights their role in transforming clinical diagnostics and improving patient care globally.